医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

APCER Life Sciences Appoints Dr. Sutinder Bindra as Global Head of Medical Affairs, Opens Hong Kong Office

2015年08月06日 PM01:01
このエントリーをはてなブックマークに追加


 

PRINCETON, N.J.

APCER Life Sciences, the truly global provider of safety, medical, regulatory, and technology services, announced today that Sutinder Bindra, MD, has joined the company as Global Head of Medical Affairs. Dr. Bindra, who was most recently Head of Medical and Clinical Affairs for Pfizer’s Asia-Pacific Region, will lead a fully integrated team to provide Medical Affairs services globally, including the Asia Pacific region, from APCER’s newly established office in Hong Kong.

“Our desire is to continually strengthen and expand both the range of services we provide and our local presence throughout the world,” said Suneet Walia, CEO of APCER Life Sciences, Inc. “Dr. Bindra’s extensive experience and demonstrated leadership in medical and clinical affairs are precisely what we need to build our global capabilities and help our clients with the challenges of developing and marketing pharmaceuticals in a resource-constrained environment.”

Dr. Bindra worked for Pfizer and its legacy companies for more than seventeen years. As Head of Pfizer’s Asia Medical and Regulatory Operations in Hong Kong, Dr. Bindra grew the organization to include a multitude of new functions and responsibilities, including the expansion of clinical research and drug development in Asia; creation of the Outcomes Research and Health Technology Assessment functions; implementation of new technology platforms for Medical Information; and collaboration and training with regulatory authorities. He pioneered business orientation programs for new Medical Managers, processes for the evaluation and conduct of Investigator-Initiated Research (IIR), and collaboration with key opinion leaders (KOLs).

“The importance of a global approach to Medical Affairs is growing in every organization, as the hurdles for reimbursement are becoming higher than those for regulatory approval in more and more countries,” said Dr. Bindra. “I’m pleased to join an organization that recognizes the huge role that Medical Affairs and Outcomes Research have to play in the success of pharmaceutical and device businesses and is committed to developing and delivering cohesive, technology-enabled solutions and services.”

Dr. Bindra had several years of clinical experience in Internal Medicine and Cardiology before joining the pharmaceutical industry in 1993. In addition to an MBBS and an MD in Internal Medicine, he has a Masters in Pharmaceutical Medicine from Hibernia University in Ireland; Advanced Management Certificate from the Thunderbird University, Arizona, USA; and Leadership Development Certificate from the Harvard Business School, USA. Dr. Bindra is a recipient of the WE Upjohn Award for Clinical Excellence in Pfizer and has several scientific publications to his credit.

The new APCER Life Sciences Hong Kong office is located in the Bank of East Asia Harbour View Centre in Wan Chai, at the heart of the city’s Central Business District. It overlooks the Victoria Harbour and is a short walk from the Hong Kong Convention and Exhibition Centre.

About APCER Life Sciences

APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources from around the world to ensure that patients receive the safest, most effective therapies possible.

To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; and contact APCER at one of their global offices.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150805005307/en/

CONTACT

APCER Life Sciences, Inc.
Jill Notte, 609-436-4714
Director,
Global Marketing

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent